|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
��� |
|
������ |
|
��Ƥ�ʼ����� |
| ��������������� | |
|
������ |
|
�Ź��� |
| PubMed | |
|
Article by ������ |
|
Article by �Ź��� |
����������������
������1, �Ź���2
1. ɽ��ʡƤ�����Բ������о���, ����250022;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
����������������Ϊ�����������������Ҫԭ��֮һ������ͱ����ǰ�Ƿ�������������Ƿ����������������Σ�����ء�Ӧ�������·��ֵ���综�߶��ڽ������ܼ�Ⲣ���·��������������Ƥ�ʼ������ơ���Ƥ�ʼ��ضԳ¾��������������������Ч;Ԥ�������Ʋ������Խ����·���������ķ����ʡ�
1. ɽ��ʡƤ�����Բ������о���, ����250022;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
1. ɽ��ʡƤ�����Բ������о���, ����250022;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
[2] Richardus JH, Finlay KM, Croft RP, et al. Nerve function impairment in leprosy at diagnosis and at completion of MDT:a retrospective cohort study of 786 patients in Bangladesh. Lepr Rev,1996, 67:297-305.
[3] Van Brakel WH, Khawas IB. Nerve damage in leprosy:an epidemiological and clinical study of 396 patients in west Nepal-part 1.Definitions, methods and frequencies. Lepr Rev, 1994, 65:204.
[4] Saunderson P, Gebre S, Desta K, et al. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia:definitions, incidence, risk factors and outcome. Lepr Rev, 2000, 71:285-308.
[5] Croft RP, Nicholls PG, Richardus JH, et al. Incidence rates of acute nerve function impairment in leprosy:a prospective cohort analysis after 24 months (The Bangladesh Acute Nerve Damage Study).Lepr Rev, 2000, 71:18-33.
[6] Schreuder PA. The occurrence of reactions and impairments in leprosy:experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. ��.Neural and other impairments. Int J Lepr Other Mycobact Dis,1998, 66:170-181.
[7] Kumar V, Sengupta U. Ultrastructural study of Schwann cells and endothelial cells in the pathogenesis of leprous neuropathy. Int J Lepr Other Mycobact Dis, 2003, 71:328-340.
[8] Roche PW, Le Master J, Butlin CR. Risk factors for type 1 reactions in leprosy. Int J Lepr Other Mycobact Dis, 1997, 65:450-455.
[9] Van Brakel WH, Khawas IB, Lucas SB. Reactions in leprosy:an epidemiological study of 386 patients in west Nepal. Lepr Rev,1994, 65:190-203.
[10] Lienhardt C, Fine PE. Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation? Lepr Rev,1994, 65:9-33.
[11] Nicholls PG, Croft RP, Richardus JH, et al. Delay in presentation,an indicator for nerve function status at registration and for treatment outcome-the experience of the Bangladesh Acute Nerve Damage Study cohort. Lepr Rev, 2003, 74:349-356.
[12] Ferreira J, Mengue SS, Wagner MB, et al. Estimating hidden prevalence in Hansen's disease through diagnosis delay and grade of disability at time of diagnosis. Int J Lepr Other Mycobact Dis, 2000,68:464-473.
[13] Meima A, Saunderson PR, Gebre S, et al. Factors associated with impairments in new leprosy patients:the AMFES cohort. Lepr Rev,1999, 70:189-203.
[14] van Brakel WH, Shute J, Dixon JA, et al. Evaluation of sensibility in leprosy-comparison of various clinical methods. Lepr Rev, 1994,65:106-121.
[15] Watson JM. Disability control in a leprosy control programme. Lepr Rev, 1989, 60:169-177.
[16] Anderson AM, Croft RP. Reliability of Semmes Weinstein monofilament and ballpoint sensory testing, and voluntary muscle testing in Bangladesh. Lepr Rev, 1999, 70:305-313.
[17] van Brakel WH, Khawas IB, Gurung KS,et al. Intra- and intertester reliability of sensibility testing in leprosy. Int J Lepr Other Mycobact Dis, 1996, 64:287-298.
[18] Croft RP, Richardus JH, Smith WC. Field treatment of acute nerve function impairment in leprosy using a standardized corticosteroid regimen--first year's experience with 100 patients. Lepr Rev,1997, 68:316-325.
[19] Rose P, Waters MF. Reversal reactions in leprosy and their management. Lepr Rev, 1991, 62:113-121.
[20] Lockwood DN, Vinayakumar S, Stanley JN, et al. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Int J Lepr Other Mycobact Dis, 1993, 61:8-15.
[21] Bernink EH, Voskens JE. Study on the detection of leprosy reactions and the effect of prednisone on various nerves, Indonesia.Lepr Rev, 1997, 68:225-232.
[22] Richardus JH, Withington SG, Anderson AM, et al. Treatment with corticosteroids of long-standing nerve function impairment in leprosy:a randomized controlled trial (TRIPOD 3). Lepr Rev, 2003,74:311-318.
[23] Jiang J, Watson JM, Zhang GC, et al. A field trial of detection and treatment of nerve function impairment in leprosy--report from national POD pilot project. Lepr Rev, 1998, 69:367-375.
[24] Croft RP, Nicholls PG, Richardus JH, et al. The treatment of acute nerve function impairment in leprosy:results from a prospective cohort study in Bangladesh. Lepr Rev, 2000, 71:154-168.
[25] Sharma P, Kar HK, Misra RS,et al. Reactional states and neuritis in multibacillary leprosy patients following MDT with/without immunotherapy with Mycobacterium antileprosy vaccine. Lepr Rev,2000, 71:193-205.
[26] Van Brakel WH, Anderson AM, Withington SG, et al. The prognostic importance of detecting mild sensory impairment in leprosy:a randomized controlled trial (TRIPOD 2). Lepr Rev, 2003, 74:300.
[27] Smith WC, Anderson AM, Withington SG, et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy:randomised placebo controlled trial (TRIPOD 1). BMJ, 2004, 328:1459.
[28] Richardus JH, Withington SG, Anderson AM, et al. Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy:results from the"TRIPOD" trials. Lepr Rev, 2003, 74:319-327.